Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q
By Dean Seal
Becton Dickinson raised its fiscal 2024 guidance slightly after reporting higher revenue in the first quarter, largely from its medical and interventional businesses.
The medical-device maker posted a profit of $281 million, or 96 cents a share, in the quarter ended Dec. 31, compared with $509 million, or $1.70 a share, in the same period a year ago.
Adjusting for integration costs, restructuring costs and other one-time items, adjusted earnings were $2.68 a share. Analysts polled by FactSet had been expecting $2.40 a share.
Quarterly revenue rose to $4.71 billion from $4.59 billion last year, below analyst projections for $4.73 billion, according to FactSet.
Sales in the U.S. ticked up less than 1% to $2.75 billion while international sales jumped 5.5% to $1.96 billion.
The Franklin Lakes, N.J.-based company's medical unit recorded 3.5% higher revenue at $2.23 billion. Sales in its life-sciences segment ticked down 1% to $1.29 billion while its interventional business logged 2.6% higher revenue at $1.19 billion.
Becton Dickinson is expecting revenue to rise 5.5% to 6.25% on an organic basis and 4.75% to 5.5% on a currency-neutral basis in fiscal 2024, adding a quarter of a percentage point to the low-end of its prior guidance.
The company is also expecting annual adjusted earnings to come in at $12.82 to $13.06 a share, up from a previous outlook for $12.70 to $13 a share.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 01, 2024 07:04 ET (12:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks